fda glp-1 warning november 2025 Pharmacovigilance Assessment of Compounded Receptor Agonists: Insights From the Adverse Event Reporting System FDA Drug Recalls and Warnings:

Further work is needed, but this data raises further questions about their actual use and whether appropriate safety standards are in place and being adhered to

The injectable weight-loss drug Wegovy is the only medication currently approved for cardiovascular indications in patients with overweight or obesity and existing cardiovascular disease

Balk E.M., Cooney T.G., Cross J.T., Jr., et al

Track your appetite on a simple 1 to 10 scale daily

17 In addition to these findings, the SUSTAIN-6 trial also showed that semaglutide can offer a significant reduction in the risk of new or worsening nephropathy including persistent macroalbuminuria, increase in serum creatinine or the need of renal replacement therapy

Up to 40% of total weight lost on GLP-1 drugs is lean mass (muscle), not fat